Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, Hubacek P, Navarro D, Cordonnier C and Ward KN; 2017 European Conference on Infections in Leukaemia group, : Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 19:e260–e272. 2019. View Article : Google Scholar : PubMed/NCBI

Gyurkocza B, Rezvani A and Storb RF: Allogeneic hematopoietic cell transplantation: The state of the art. Expert Rev Hematol. 3:285–299. 2010. View Article : Google Scholar : PubMed/NCBI

Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, Szer J, Lipton J, Schwendener A, Gratwohl M, et al: Hematopoietic stem cell transplantation: A global perspective. JAMA. 303:1617–1624. 2010. View Article : Google Scholar : PubMed/NCBI

Borchers S, Luther S, Lips U, Hahn N, Kontsendorn J, Stadler M, Buchholz S, Diedrich H, Eder M, Koehl U, et al: Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 13:222–236. 2011. View Article : Google Scholar : PubMed/NCBI

Moss P and Rickinson A: Cellular immunotherapy for viral infection after HSC transplantation. Nat Rev Immunol. 5:9–20. 2005. View Article : Google Scholar : PubMed/NCBI

Haidar G and Singh N: Viral infections in solid organ transplant recipients: Novel updates and a review of the classics. Curr Opin Infect Dis. 30:579–588. 2017. View Article : Google Scholar : PubMed/NCBI

Enders G, Daiminger A, Lindemann L, Knotek F, Bäder U, Exler S and Enders M: Cytomegalovirus (CMV) seroprevalence in pregnant women, bone marrow donors and adolescents in Germany, 1996–2010. Med Microbiol Immunol. 201:303–309. 2012. View Article : Google Scholar : PubMed/NCBI

Ouédraogo AS, Yaméogo JT, Poda GEA, Kientega Y and Ouédraogo Traore R: Prevalence of anti-CMV antibodies in blood donors in Ouagadougou (Burkina Faso). Med Sante Trop. 22:107–109. 2012.PubMed/NCBI

Revello MG, Vauloup-Fellous C, Grangeot-Keros L, van Helden J, Dickstein Y, Lipkin I, Mühlbacher A and Lazzarotto T: Clinical evaluation of new automated cytomegalovirus IgM and IgG assays for the Elecsys(^®) analyser platform. Eur J Clin Microbiol Infect Dis. 31:3331–3339. 2012. View Article : Google Scholar : PubMed/NCBI

Strand KM, Odland ML, Iversen AC, Nordbø SA, Vik T and Austgulen R: Cytomegalovirus antibody status at 17–18 weeks of gestation and pre-eclampsia: A case-control study of pregnant women in Norway. BJOG. 119:1316–1323. 2012. View Article : Google Scholar : PubMed/NCBI

Amsler L, Verweij M and DeFilippis VR: The tiers and dimensions of evasion of the type I interferon response by human cytomegalovirus. J Mol Biol. 425:4857–4871. 2013. View Article : Google Scholar : PubMed/NCBI

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2013. View Article : Google Scholar

Boeckh M and Ljungman P: How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 113:5711–5719. 2009. View Article : Google Scholar : PubMed/NCBI

Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, Chee MS, Hutchison CA III, Kouzarides T, Martignetti JA, Preddie E, et al: The DNA sequence of the human cytomegalovirus genome. DNA Seq. 2:1–12. 1991. View Article : Google Scholar : PubMed/NCBI

Murphy E and Shenk T: Human cytomegalovirus genome. Curr Top Microbiol Immunol. 325:1–19. 2008.PubMed/NCBI

Scherer M, Schilling EM and Stamminger T: The human CMV IE1 protein: An offender of PML NUCLEAR BOdies. Adv Anat Embryol Cell Biol. 223:77–94. 2017. View Article : Google Scholar : PubMed/NCBI

Fox HL, Dembowski JA and DeLuca NA: A herpesviral immediate early protein promotes transcription elongation of viral transcripts. mBio. 8:e00745–17. 2017. View Article : Google Scholar : PubMed/NCBI

Gardner TJ and Tortorella D: Virion glycoprotein-mediated immune evasion by human cytomegalovirus: A sticky virus makes a slick getaway. Microbiol Mol Biol Rev. 80:663–677. 2016. View Article : Google Scholar : PubMed/NCBI

Sezgin E, An P and Winkler CA: Host genetics of cytomegalovirus pathogenesis. Front Genet. 10:6162019. View Article : Google Scholar : PubMed/NCBI

Cheung AK, Gottlieb DJ, Plachter B, Pepperl-Klindworth S, Avdic S, Cunningham AL, Abendroth A and Slobedman B: The role of the human cytomegalovirus UL111A gene in down-regulating CD4⁺ T-cell recognition of latently infected cells: Implications for virus elimination during latency. Blood. 114:4128–4137. 2009. View Article : Google Scholar : PubMed/NCBI

Slavuljica I, Busche A, Babić M, Mitrović M, Gašparović I, Cekinović D, Markova Car E, Pernjak Pugel E, Ciković A, Lisnić VJ, et al: Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. J Clin Invest. 120:4532–4545. 2010. View Article : Google Scholar : PubMed/NCBI

Griffiths PD: Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation. Lancet Infect Dis. 12:790–798. 2012. View Article : Google Scholar : PubMed/NCBI

Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, Aicheler R, McSharry BP, Rickards CR, Cochrane D, Llewellyn-Lacey S, et al: Modulation of natural killer cells by human cytomegalovirus. J Clin Virol. 41:206–212. 2008. View Article : Google Scholar : PubMed/NCBI

Fang D and Zhu J: Molecular switches for regulating the differentiation of inflammatory and IL-10-producing anti-inflammatory T-helper cells. Cell Mol Life Sci. 77:289–303. 2020. View Article : Google Scholar : PubMed/NCBI

Zhou L, Chong MM and Littman DR: Plasticity of CD4⁺ T cell lineage differentiation. Immunity. 30:646–655. 2009. View Article : Google Scholar : PubMed/NCBI

Opal SM and DePalo VA: Anti-inflammatory cytokines. Chest. 117:1162–1172. 2000. View Article : Google Scholar : PubMed/NCBI

McSharry BP, Avdic S and Slobedman B: Human cytomegalovirus encoded homologs of cytokines, chemokines and their receptors: Roles in immunomodulation. Viruses. 4:2448–2470. 2012. View Article : Google Scholar : PubMed/NCBI

Barel MT, Ressing M, Pizzato N, van Leeuwen D, Le Bouteiller P, Lenfant F and Wiertz EJ: Human cytomegalovirus-encoded US2 differentially affects surface expression of MHC class I locus products and targets membrane-bound, but not soluble HLA-G1 for degradation. J Immunol. 171:6757–6765. 2003. View Article : Google Scholar : PubMed/NCBI

Khan N, Bruton R, Taylor GS, Cobbold M, Jones TR, Rickinson AB and Moss PA: Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes. J Virol. 79:2869–2879. 2005. View Article : Google Scholar : PubMed/NCBI

Ciáurriz M, Zabalza A, Beloki L, Mansilla C, Pérez-Valderrama E, Lachén M, Bandrés E, Olavarría E and Ramírez N: The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients. Cell Mol Life Sci. 72:4049–4062. 2015. View Article : Google Scholar : PubMed/NCBI

Minton K: Viral immunity: How CMV bypasses immune memory. Nat Rev Immunol. 10:2882010. View Article : Google Scholar : PubMed/NCBI

Reddehase MJ and Lemmermann NAW: Cellular reservoirs of latent cytomegaloviruses. Med Microbiol Immunol. 208:391–403. 2019. View Article : Google Scholar : PubMed/NCBI

Sinzger C, Digel M and Jahn G: Cytomegalovirus cell tropism. Curr Top Microbiol Immunol. 325:63–83. 2008.PubMed/NCBI

Higdon LE, Trofe-Clark J, Liu S, Margulies KB, Sahoo MK, Blumberg E, Pinsky BA and Maltzman JS: Cytomegalovirus-responsive CD8⁺ T cells expand after solid organ transplantation in the absence of CMV disease. Am J Transplant. 17:2045–2054. 2017. View Article : Google Scholar : PubMed/NCBI

Albiero E, Amati E, Baumeister E, Einsele H, Grigoleit GU and Rodeghiero F: Heterogeneity of Specific CD4⁺ and CD8⁺ T cells stimulated by CMV pp65 and IE1 antigens. J Immunother. 39:329–342. 2016. View Article : Google Scholar : PubMed/NCBI

Styczynski J: Who is the patient at risk of CMV recurrence: A review of the current scientific evidence with a focus on hematopoietic cell transplantation. Infect Dis Ther. 7:1–16. 2018. View Article : Google Scholar : PubMed/NCBI

Cho SY, Lee DG and Kim HJ: Cytomegalovirus infections after hematopoietic stem cell transplantation: Current status and future immunotherapy. Int J Mol Sci. 20:26662019. View Article : Google Scholar

Kim SJ, Varghese TK, Zhang Z, Zhao LC, Thomas G, Hummel M and Abecassis M: Renal ischemia/reperfusion injury activates the enhancer domain of the human cytomegalovirus major immediate early promoter. Am J Transplant. 5:1606–1613. 2005. View Article : Google Scholar : PubMed/NCBI

Kurata K, Yakushijin K, Mizuno I, Gomyo H, Okamura A, Ichikawa H, Sakai R, Mizutani Y, Kakiuchi S, Miyata Y, et al: Early lymphocyte recovery predicts clinical outcome after HSCT with mycophenolate mofetil prophylaxis in the Japanese population. Int J Hematol. 108:58–65. 2018. View Article : Google Scholar : PubMed/NCBI

Theobald SJ, Khailaie S, Meyer-Hermann M, Volk V, Olbrich H, Danisch S, Gerasch L, Schneider A, Sinzger C, Schaudien D, et al: Signatures of T and B cell development, functional responses and PD-1 upregulation after HCMV latent infections and reactivations in Nod.Rag.Gamma mice humanized with cord blood CD34⁺ cells. Front Immunol. 9:27342018. View Article : Google Scholar : PubMed/NCBI

Camargo JF, Wieder ED, Kimble E, Benjamin CL, Kolonias DS, Kwon D, Chen XS and Komanduri KV: Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation. Blood. 133:867–877. 2019. View Article : Google Scholar : PubMed/NCBI

van Gent R, Metselaar HJ and Kwekkeboom J: Immunomodulation by hyperimmunoglobulins after solid organ transplantation: Beyond prevention of viral infection. Transplant Rev (Orlando). 31:78–86. 2017. View Article : Google Scholar : PubMed/NCBI

Prösch S, Wendt CE, Reinke P, Priemer C, Oppert M, Krüger DH, Volk HD and Döcke WD: A novel link between stress and human cytomegalovirus (HCMV) infection: Sympathetic hyperactivity stimulates HCMV activation. Virology. 272:357–365. 2000. View Article : Google Scholar : PubMed/NCBI

Atabani SF, Smith C, Atkinson C, Aldridge RW, Rodriguez-Perálvarez M, Rolando N, Harber M, Jones G, O'Riordan A, Burroughs AK, et al: Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant. 12:2457–2464. 2012. View Article : Google Scholar : PubMed/NCBI

Yong MK, Lewin SR and Manuel O: Immune monitoring for CMV in transplantation. Curr Infect Dis Rep. 20:42018. View Article : Google Scholar : PubMed/NCBI

Blyth E, Withers B, Clancy L and Gottlieb D: CMV-specific immune reconstitution following allogeneic stem cell transplantation. Virulence. 7:967–980. 2016. View Article : Google Scholar : PubMed/NCBI

Król L, Stuchlý J, Hubáček P, Keslová P, Sedláček P, Starý J, Hrušák O and Kalina T: Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT. Bone Marrow Transplant. 46:1089–1098. 2011. View Article : Google Scholar : PubMed/NCBI

Lilleri D, Gerna G, Zelini P, Chiesa A, Rognoni V, Mastronuzzi A, Giorgiani G, Zecca M and Locatelli F: Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation. PLoS One. 7:e416482012. View Article : Google Scholar : PubMed/NCBI

Reusser P, Riddell SR, Meyers JD and Greenberg PD: Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 78:1373–1380. 1991. View Article : Google Scholar : PubMed/NCBI

Ogonek J, Varanasi P, Luther S, Schweier P, Kühnau W, Göhring G, Dammann E, Stadler M, Ganser A, Borchers S, et al: Possible impact of cytomegalovirus-specific CD8⁺ T cells on immune reconstitution and conversion to complete donor chimerism after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 23:1046–1053. 2017. View Article : Google Scholar : PubMed/NCBI

Hill GR, Kuns RD, Raffelt NC, Don AL, Olver SD, Markey KA, Wilson YA, Tocker J, Alexander WS, Clouston AD, et al: SOCS3 regulates graft-versus-host disease. Blood. 116:287–296. 2010. View Article : Google Scholar : PubMed/NCBI

Alexander WS: Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol. 2:410–416. 2002. View Article : Google Scholar : PubMed/NCBI

Lee TH, Lee JY, Park S, Shin SH, Yahng SA, Yoon JH, Lee SE, Cho BS, Kim YJ, Lee S, et al: Expression of SOCS1 and SOCS3 genes in human graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Res. 48:16–23. 2013. View Article : Google Scholar : PubMed/NCBI

Shin SH, Lee JY, Lee TH, Park SH, Yahng SA, Yoon JH, Lee SE, Cho BS, Lee DG, Kim YJ, et al: SOCS1 and SOCS3 are expressed in mononuclear cells in human cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation. Blood Res. 50:40–45. 2015. View Article : Google Scholar : PubMed/NCBI

Meyers JD, Flournoy N and Thomas ED: Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 153:478–488. 1986. View Article : Google Scholar : PubMed/NCBI

Kuo HT, Ye X, Sampaio MS, Reddy P and Bunnapradist S: Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis. Transplantation. 90:1091–1098. 2010. View Article : Google Scholar : PubMed/NCBI

Nichols WG, Corey L, Gooley T, Davis C and Boeckh M: High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection. J Infect Dis. 185:273–282. 2002. View Article : Google Scholar : PubMed/NCBI

Schnitzler MA, Woodward RS, Brennan DC, Spitznagel EL, Dunagan WC and Bailey TC: Impact of cytomegalovirus serology on graft survival in living related kidney transplantation: Implications for donor selection. Surgery. 121:563–568. 1997. View Article : Google Scholar : PubMed/NCBI

Gerstenkorn C, Balupuri S, Mohamed MA, Manas DM, Ali S, Kirby J and Talbot D: The impact of cytomegalovirus serology for 7-year graft survival in cadaveric kidney transplantation-the Newcastle experience. Transpl Int. 13 (Suppl 1):S372–S374. 2000. View Article : Google Scholar : PubMed/NCBI

Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A and Johannessen I: High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol. 85:893–898. 2013. View Article : Google Scholar : PubMed/NCBI

Amouzegar A, Dey BR and Spitzer TR: Peripheral blood or bone marrow stem cells? Practical considerations in hematopoietic stem cell transplantation. Transfus Med Rev. 33:43–50. 2019. View Article : Google Scholar : PubMed/NCBI

Trenschel R, Ross S, Hüsing J, Ottinger H, Elmaagacli A, Roggendorf M, Schaefer UW and Runde V: Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant. 25:665–672. 2000. View Article : Google Scholar : PubMed/NCBI

Uppuluri R, Subburaj D, Jayaraman D, Swaminathan VV, Mullanfiroze K, Vaidhyanathan L and Raj R: Cytomegalovirus reactivation posthematopoietic stem cell transplantation (HSCT) and type of graft: A step toward rationalizing CMV testing and positively impacting the economics of HSCT in developing countries. Pediatr Blood Cancer. 64:2017.doi: 10.1002/pbc.26639. View Article : Google Scholar

Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G and Bowden RA: Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood. 88:4063–4071. 1996. View Article : Google Scholar : PubMed/NCBI

Gatault P, Al-Hajj S, Noble J, Chevallier E, Piollet M, Forconi C, Gaudy-Graffin C, Thibault G, Miquelestorena-Standley E, Halimi JM, et al: CMV-infected kidney grafts drive the expansion of blood-borne CMV-specific T cells restricted by shared class I HLA molecules via presentation on donor cells. Am J Transplant. 18:1904–1913. 2018. View Article : Google Scholar : PubMed/NCBI

Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, et al: Broadly targeted human cytomegalovirus-specific CD4⁺ and CD8⁺ T cells dominate the memory compartments of exposed subjects. J Exp Med. 202:673–685. 2005. View Article : Google Scholar : PubMed/NCBI

Essa S, Pacsa A, Said T, Nampoory MR, Raghupathy R, Johny KV, Al-Nakib W and Al-Mosawy M: Is combined pretransplantation seropositivity of kidney transplant recipients for cytomegalovirus antigens (pp150 and pp28) a predictor for protection against infection? Med Princ Pract. 17:66–70. 2008. View Article : Google Scholar : PubMed/NCBI

Wills MR, Okecha G, Weekes MP, Gandhi MK, Sissons PJ and Carmichael AJ: Identification of naive or antigen-experienced human CD8⁺ T cells by expression of costimulation and chemokine receptors: Analysis of the human cytomegalovirus-specific CD8⁺ T cell response. J Immunol. 168:5455–5464. 2002. View Article : Google Scholar : PubMed/NCBI

Maecker HT and Maino VC: Analyzing T-cell responses to cytomegalovirus by cytokine flow cytometry. Hum Immunol. 65:493–499. 2004. View Article : Google Scholar : PubMed/NCBI

Baumann NS, Welten SPM, Torti N, Pallmer K, Borsa M, Barnstorf I, Oduro JD, Cicin-Sain L and Oxenius A: Early primed KLRG1-CMV-specific T cells determine the size of the inflationary T cell pool. PLoS Pathog. 15:e10077852019. View Article : Google Scholar : PubMed/NCBI

Scheinberg P, Melenhorst JJ, Brenchley JM, Hill BJ, Hensel NF, Chattopadhyay PK, Roederer M, Picker LJ, Price DA, Barrett AJ and Douek DC: The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. Blood. 114:5071–5080. 2009. View Article : Google Scholar : PubMed/NCBI

Liu J, Chang YJ, Yan CH, Xu LP, Jiang ZF, Zhang XH, Liu KY and Huang XJ: Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation. J Infect. 73:261–270. 2016. View Article : Google Scholar : PubMed/NCBI

LaMattina JC, Mezrich JD, Hofmann RM, Foley DP, D'Alessandro AM, Sollinger HW and Pirsch JD: Alemtuzumab as compared to alternative contemporary induction regimens. Transpl Int. 25:518–526. 2012. View Article : Google Scholar : PubMed/NCBI

Wang QY, Dong YJ, Liang ZY, Yin Y, Liu W, Xu WL, Sun YH, Han N, Li Y and Ren HY: Clinical analysis for patients with AML treated after Allo-HSCT. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 28:1105–1114. 2020.(In Chinese). PubMed/NCBI

Kanter J, Pallardó L, Gavela E, Escudero V, Beltrán S, Morales A, Avila A and Crespo JF: Cytomegalovirus infection renal transplant recipients: Risk factors and outcome. Transplant Proc. 41:2156–2158. 2009. View Article : Google Scholar : PubMed/NCBI

Hosseini-Moghaddam SM, Rotstein C and Husain S: Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant. 11:4072011. View Article : Google Scholar : PubMed/NCBI

Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, Eisen HJ, Salm K, Tolzman D, Gao J, et al: Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 6:1377–1386. 2006. View Article : Google Scholar : PubMed/NCBI

Viganò M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y and Delgado JF; RAD A2411 Study Investigators, : Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: A randomized, multicenter study. Transpl Infect Dis. 12:23–30. 2010. View Article : Google Scholar : PubMed/NCBI

Axelrod D, Leventhal JR, Gallon LG, Parker MA and Kaufman DB: Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients. Am J Transplant. 5:1423–1429. 2005. View Article : Google Scholar : PubMed/NCBI

Ekberg H, Bernasconi C, Nöldeke J, Yussim A, Mjörnstedt L, Erken U, Ketteler M and Navrátil P: Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant. 25:2004–2010. 2010. View Article : Google Scholar : PubMed/NCBI

Muffly L, Sheehan K, Armstrong R, Jensen K, Tate K, Rezvani AR, Miklos D, Arai S, Shizuru J, Johnston L, et al: Infusion of donor-derived CD8⁺ memory T cells for relapse following allogeneic hematopoietic cell transplantation. Blood Adv. 2:681–690. 2018. View Article : Google Scholar : PubMed/NCBI

Teijaro JR: Cytokine storms in infectious diseases. Semin Immunopathol. 39:501–503. 2017. View Article : Google Scholar : PubMed/NCBI

Miller W, Flynn P, McCullough J, Balfour HH Jr, Goldman A, Haake R, McGlave P, Ramsay N and Kersey J: Cytomegalovirus infection after bone marrow transplantation: An association with acute graft-v-host disease. Blood. 67:1162–1167. 1986. View Article : Google Scholar : PubMed/NCBI

Stern A and Papanicolaou GA: CMV prevention and treatment in transplantation: What's New in 2019. Curr Infect Dis Rep. 21:452019. View Article : Google Scholar : PubMed/NCBI

Murata M, Ikegame K, Morishita Y, Ogawa H, Kaida K, Nakamae H, Ikeda T, Nishida T, Inoue M, Eto T, et al: Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: An analysis of the JSHCT. Bone Marrow Transplant. 52:252–257. 2017. View Article : Google Scholar : PubMed/NCBI

Lin HC, Han SM, Hwang WL, Chou CW, Chang KH, Shi ZY and Jerry Teng CL: Cytomegalovirus infection and treatment in allogeneic hematopoietic stem cell transplantation: A retrospective study from a single institution in an endemic area. Turk J Haematol. 34:159–166. 2017. View Article : Google Scholar : PubMed/NCBI

Xue H, Hu Y, Feng S, Liu Z and Gao F: Risk factor analysis for cytomegalovirus infection after peripheral blood allogeneic hematopoietic stem cell transplantation. J China Med Univ. 48:417–420. 2019.

Fuji S, Einsele H and Kapp M: Cytomegalovirus disease in hematopoietic stem cell transplant patients: Current and future therapeutic options. Curr Opin Infect Dis. 30:372–376. 2017. View Article : Google Scholar : PubMed/NCBI

Park SY, Lee SO, Choi SH, Kim YS, Woo JH, Baek S, Sung H, Kim MN, Kim DY, Lee JH, et al: Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: A prospective observational study. J Antimicrob Chemother. 67:1486–1492. 2012. View Article : Google Scholar : PubMed/NCBI

Zhu MX, Wan WL, Li HS, Wang J, Wang YF, Hu K and Ke XY: Early immune reconstitution after hematopoietic stem cell transplantation. Beijing Da Xue Xue Bao Yi Xue Ban. 48:515–522. 2016.(In Chinese). PubMed/NCBI

Yong MK, Cameron PU, Slavin M, Morrissey CO, Bergin K, Spencer A, Ritchie D, Cheng AC, Samri A, Carcelain G, et al: Identifying cytomegalovirus complications using the quantiferon-CMV assay after allogeneic hematopoietic stem cell transplantation. J Infect Dis. 215:1684–1694. 2017. View Article : Google Scholar : PubMed/NCBI

Wagner-Drouet E, Teschner D, Wolschke C, Janson D, Schäfer-Eckart K, Gärtner J, Mielke S, Schreder M, Kobbe G, Kondakci M, et al: Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. Haematologica. 106:363–374. 2021. View Article : Google Scholar : PubMed/NCBI

El Haddad L, Ariza-Heredia E, Shah DP, Jiang Y, Blanchard T, Ghantoji SS, El Chaer F, El-Haddad D, Prayag A, Nesher L, et al: The ability of a cytomegalovirus ELISPOT assay to predict outcome of low-level CMV reactivation in hematopoietic cell transplant recipients. J Infect Dis. 219:898–907. 2019. View Article : Google Scholar : PubMed/NCBI

Krawczyk A, Ackermann J, Goitowski B, Trenschel R, Ditschkowski M, Timm J, Ottinger H, Beelen DW, Grüner N and Fiedler M: Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real time PCR. J Clin Virol. 99-100:61–66. 2018. View Article : Google Scholar : PubMed/NCBI

Cao K, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Daher M, Wang Q, Li L, Saliba RM, et al: Donor NKG2C copy number: An independent predictor for CMV reactivation after double cord blood transplantation. Front Immunol. 9:24442018. View Article : Google Scholar : PubMed/NCBI

Albert E, Solano C, Giménez E, Focosi D, Pérez A, Macera L, Piñana JL, Boluda JCH, Maggi F and Navarro D: The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 53:180–187. 2018. View Article : Google Scholar : PubMed/NCBI

Takahashi R, Nakatsukasa H, Shiozawa S and Yoshimura A: SOCS1 is a key molecule that prevents regulatory T cell plasticity under inflammatory conditions. J Immunol. 199:149–158. 2017. View Article : Google Scholar : PubMed/NCBI

Lodding IP, Schultz HH, Jensen JU, Kirkby N, Perch M, Andersen C, Lundgren JD and Iversen M: Cytomegalovirus viral load in bronchoalveolar lavage to diagnose lung transplant associated CMV pneumonia. Transplantation. 102:326–332. 2018. View Article : Google Scholar : PubMed/NCBI

Bhatia J, Shah BV, Mehta AP, Deshmukh M, Sirsat RA and Rodrigues C: Comparing serology, antigenemia assay and polymerase chain reaction for the diagnosis of cytomegalovirus infection in renal transplant patients. J Assoc Physicians India. 52:297–300. 2004.PubMed/NCBI

Griscelli F, Barrois M, Chauvin S, Lastere S, Bellet D and Bourhis JH: Quantification of human cytomegalovirus DNA in bone marrow transplant recipients by real-time PCR. J Clin Microbiol. 39:4362–4369. 2001. View Article : Google Scholar : PubMed/NCBI

Drew WL: Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients. Curr Opin Infect Dis. 20:408–411. 2007. View Article : Google Scholar : PubMed/NCBI

Pollack M, Heugel J, Xie H, Leisenring W, Storek J, Young JA, Kukreja M, Gress R, Tomblyn M and Boeckh M: An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 17:664–673. 2011. View Article : Google Scholar : PubMed/NCBI

Malouli D, Hansen SG, Nakayasu ES, Marshall EE, Hughes CM, Ventura AB, Gilbride RM, Lewis MS, Xu G, Kreklywich C, et al: Cytomegalovirus pp65 limits dissemination but is dispensable for persistence. J Clin Invest. 124:1928–1944. 2014. View Article : Google Scholar : PubMed/NCBI

Lee H, Park KH, Ryu JH, Choi AR, Yu JH, Lim J, Han K, Kim SI, Yang CW, Chung BH and Oh EJ: Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients. PLoS One. 12:e01894882017. View Article : Google Scholar : PubMed/NCBI

Lisboa LF, Asberg A, Kumar D, Pang X, Hartmann A, Preiksaitis JK, Pescovitz MD, Rollag H, Jardine AG and Humar A: The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation. 91:231–236. 2011. View Article : Google Scholar : PubMed/NCBI

Gerna G, Lilleri D, Caldera D, Furione M, Zenone Bragotti L and Alessandrino EP: Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 41:873–879. 2008. View Article : Google Scholar : PubMed/NCBI

Boeckh M, Stevens-Ayers T, Travi G, Huang M-L, Cheng GS, Xie H, Leisenring W, Erard V, Seo S, Kimball L, et al: Cytomegalovirus (CMV) DNA quantitation in bronchoalveolar lavage fluid from hematopoietic stem cell transplant recipients with CMV pneumonia. J Infect Dis. 215:1514–1522. 2017. View Article : Google Scholar : PubMed/NCBI

Beam E, Germer JJ, Lahr B, Yao JDC, Limper AH, Binnicker MJ and Razonable RR: Cytomegalovirus (CMV) DNA quantification in bronchoalveolar lavage fluid of immunocompromised patients with CMV pneumonia. Clin Transplant. 32:2018.doi: 10.1111/ctr.13149. View Article : Google Scholar : PubMed/NCBI

Hebart H, Rudolph T, Loeffler J, Middeldorp J, Ljubicic T, Jahn G and Einsele H: Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant. 30:181–187. 2002. View Article : Google Scholar : PubMed/NCBI

Rea F, Potena L, Yonan N, Wagner F and Calabrese F: Cytomegalovirus hyper immunoglobulin for CMV prophylaxis in thoracic transplantation. Transplantation. 100 (Suppl 3):S19–S26. 2016. View Article : Google Scholar : PubMed/NCBI

Kotton CN: CMV: Prevention, diagnosis and therapy. Am J Transplant. 13 (Suppl 3):S24–S40. 2013. View Article : Google Scholar

Griffiths PD: An explanation for posttransplant late-onset disease associated with CMV prophylaxis. Rev Med Virol. 29:e20802019. View Article : Google Scholar : PubMed/NCBI

Vamvakas EC: Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev. 19:181–199. 2005. View Article : Google Scholar : PubMed/NCBI

Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED and Meyers JD: Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 314:1006–1010. 1986. View Article : Google Scholar : PubMed/NCBI

Ljungman P, Larsson K, Kumlien G, Aschan J, Barkholt L, Gustafsson-Jernberg A, Lewensohn-Fuchs I and Ringdén O: Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors. Scand J Infect Dis. 34:347–350. 2002. View Article : Google Scholar : PubMed/NCBI

Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D and Zaia JA: Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 7:343–351. 2001. View Article : Google Scholar : PubMed/NCBI

Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L and Shpilberg O: Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: Systematic review and meta-analysis. J Clin Oncol. 27:770–781. 2009. View Article : Google Scholar : PubMed/NCBI

Alexander BT, Hladnik LM, Augustin KM, Casabar E, McKinnon PS, Reichley RM, Ritchie DJ, Westervelt P and Dubberke ER: Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy. 30:554–561. 2010. View Article : Google Scholar : PubMed/NCBI

Malagola M, Greco R, Santarone S, Natale A, Iori AP, Quatrocchi L, Barbieri W, Bruzzese A, Leotta S, Carotti A, et al: CMV management with specific immunoglobulins: A multicentric retrospective analysis on 92 allotransplanted patients. Mediterr J Hematol Infect Dis. 11:e20190482019. View Article : Google Scholar : PubMed/NCBI

Grossi P, Mohacsi P, Szabolcs Z and Potena L: Cytomegalovirus immunoglobulin after thoracic transplantation: An overview. Transplantation. 100 (Suppl 3):S1–S4. 2016. View Article : Google Scholar : PubMed/NCBI

Hammerstrom AE, Lombardi LR, Pingali SR, Rondon G, Chen J, Milton DR, Chemaly RF, Champlin RE, Gulbis A and Ciurea SO: Prevention of cytomegalovirus reactivation in haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 24:353–358. 2018. View Article : Google Scholar : PubMed/NCBI

Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers ME, Stevens-Ayers T, Jerome KR and Leisenring W: Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A randomized trial. Ann Intern Med. 162:1–10. 2015. View Article : Google Scholar : PubMed/NCBI

Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, Sorror ML, Goyal S, Özkök S, Yi J, et al: Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: A retrospective cohort study. Lancet Haematol. 3:e119–e127. 2016. View Article : Google Scholar : PubMed/NCBI

Wloch MK, Smith LR, Boutsaboualoy S, Reyes L, Han C, Kehler J, Smith HD, Selk L, Nakamura R, Brown JM, et al: Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis. 197:1634–1642. 2008. View Article : Google Scholar : PubMed/NCBI

Schleiss MR: Cytomegalovirus vaccines under clinical development. J Virus Erad. 2:198–207. 2016. View Article : Google Scholar : PubMed/NCBI

Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Guterwill DF, Smith LR, Rolland AP and Kenney RT: A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 12:290–299. 2012. View Article : Google Scholar : PubMed/NCBI

Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, et al: Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial. Lancet. 377:1256–1263. 2011. View Article : Google Scholar : PubMed/NCBI

Vincenti F, Budde K, Merville P, Shihab F, Ram Peddi V, Shah M, Wyburn K, Cassuto-Viguier E, Weidemann A, Lee M, et al: A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor. Am J Transplant. 18:2945–2954. 2018. View Article : Google Scholar : PubMed/NCBI

Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, Stevens-Ayers T, Edmison B, Boeckh M and Limaye AP: Effect of preemptive therapy vs. antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: A randomized clinical trial. JAMA. 323:1378–1387. 2020. View Article : Google Scholar : PubMed/NCBI

Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, Mackes P, Herter M, Klingebiel T, Löffler J, et al: Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 86:2815–2820. 1995. View Article : Google Scholar : PubMed/NCBI

Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ; Center for International Blood and Marrow Researchm, ; et al: Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant. 15:1143–1238. 2009. View Article : Google Scholar : PubMed/NCBI

Natori Y, Alghamdi A, Tazari M, Miller V, Husain S, Komatsu T, Griffiths P, Ljungman P, Orchanian-Cheff A, Kumar D, et al: Use of viral load as a surrogate marker in clinical studies of cytomegalovirus in solid organ transplantation: A systematic review and meta-analysis. Clin Infect Dis. 66:617–631. 2018. View Article : Google Scholar : PubMed/NCBI

Locatelli F, Bertaina A, Bertaina V and Merli P: Cytomegalovirus in hematopoietic stem cell transplant recipients-management of infection. Expert Rev Hematol. 9:1093–1105. 2016. View Article : Google Scholar : PubMed/NCBI

Limaye AP, Stapleton RD, Peng L, Gunn SR, Kimball LE, Hyzy R, Exline MC, Files DC, Morris PE, Frankel SK, et al: Effect of ganciclovir on IL-6 levels among cytomegalovirus-seropositive adults with critical Illness: A randomized clinical trial. JAMA. 318:731–740. 2017. View Article : Google Scholar : PubMed/NCBI

Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N and Pescovitz MD; Valganciclovir Solid Organ Transplant Study Group, : Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 4:611–620. 2004. View Article : Google Scholar : PubMed/NCBI

Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC and Champlin RE: Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med. 118:179–184. 1993. View Article : Google Scholar : PubMed/NCBI

Griffiths P, Whitley R, Snydman DR, Singh N and Boeckh M; International Herpes Management Forum, : Contemporary management of cytomegalovirus infection in transplant recipients: Guidelines from an IHMF workshop, 2007. Herpes. 15:4–12. 2008.PubMed/NCBI

Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB and Territo MC; Valacyclovir Cytomegalovirus Study Group, : Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis. 36:749–758. 2003. View Article : Google Scholar : PubMed/NCBI

Rubin RH, Lynch P, Pasternack MS, Schoenfeld D and Medearis DN Jr: Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice. Antimicrob Agents Chemother. 33:1975–1979. 1989. View Article : Google Scholar : PubMed/NCBI

Lukacova V, Goelzer P, Reddy M, Greig G, Reigner B and Parrott N: A physiologically based pharmacokinetic model for ganciclovir and its prodrug valganciclovir in adults and children. AAPS J. 18:1453–1463. 2016. View Article : Google Scholar : PubMed/NCBI

Weiner RS, Bortin MM, Gale RP, Gluckman E, Kay HE, Kolb HJ, Hartz AJ and Rimm AA: Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors. Ann Intern Med. 104:168–175. 1986. View Article : Google Scholar : PubMed/NCBI

Maffini E, Giaccone L, Festuccia M, Brunello L, Busca A and Bruno B: Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol. 9:585–596. 2016. View Article : Google Scholar : PubMed/NCBI

Ritchie BM, Barreto JN, Barreto EF, Crow SA, Dierkhising RA, Jannetto PJ, Tosh PK and Razonable RR: Relationship of ganciclovir therapeutic drug monitoring with clinical efficacy and patient safety. Antimicrob Agents Chemother. 63:e01855–18. 2019. View Article : Google Scholar : PubMed/NCBI

Kim ST, Lee MH, Kim SY, Kim SJ, Kim DH, Jang JH, Kim K, Kim WS and Jung CW: A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 91:886–891. 2010. View Article : Google Scholar : PubMed/NCBI

El Chaer F, Shah DP and Chemaly RF: How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood. 128:2624–2636. 2016. View Article : Google Scholar : PubMed/NCBI

Einsele H, Reusser P, Bornhäuser M, Kalhs P, Ehninger G, Hebart H, Chalandon Y, Kröger N, Hertenstein B and Rohde F: Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood. 107:3002–3008. 2006. View Article : Google Scholar : PubMed/NCBI

Barkam C, Kamal H, Dammann E, Diedrich H, Buchholz S, Eder M, Krauter J, Ganser A and Stadler M: Improving safety of preemptive therapy with oral valganciclovir for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Bone Marrow Res. 2012:8746012012. View Article : Google Scholar : PubMed/NCBI

Moretti S, Zikos P, Van Lint MT, Tedone E, Occhini D, Gualandi F, Lamparelli T, Mordini N, Berisso G, Bregante S, et al: Forscarnet vs. ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): A randomised study. Bone Marrow Transplant. 22:175–180. 1998. View Article : Google Scholar : PubMed/NCBI

Meesing A and Razonable RR: New developments in the management of cytomegalovirus infection after transplantation. Drugs. 78:1085–1103. 2018. View Article : Google Scholar : PubMed/NCBI

Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, et al: Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 377:2433–2444. 2017. View Article : Google Scholar : PubMed/NCBI

Bowman LJ, Melaragno JI and Brennan DC: Letermovir for the management of cytomegalovirus infection. Expert Opin Investig Drugs. 26:235–241. 2017. View Article : Google Scholar : PubMed/NCBI

Phoompoung P, Ferreira VH, Tikkanen J, Husain S, Viswabandya A, Kumar D and Humar A: Letermovir as salvage therapy for Cytomegalovirus infection in transplant recipients. Transplantation. 104:404–409. 2019. View Article : Google Scholar

Popping S, Dalm VASH, Lübke N, Cristanziano VD, Kaiser R, Boucher CAB and Van Kampen JJA: Emergence and persistence of letermovir-resistant cytomegalovirus in a patient with primary immunodeficiency. Open Forum Infectious Diseases. 6:ofz3752019. View Article : Google Scholar : PubMed/NCBI

Griffiths P and Lumley S: Cytomegalovirus. Curr Opin Infect Dis. 27:554–559. 2014. View Article : Google Scholar : PubMed/NCBI

Beadle JR, Hartline C, Aldern KA, Rodriguez N, Harden E, Kern ER and Hostetler KY: Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother. 46:2381–2386. 2002. View Article : Google Scholar : PubMed/NCBI

Bidanset DJ, Beadle JR, Wan WB, Hostetler KY and Kern ER: Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis. 190:499–503. 2004. View Article : Google Scholar : PubMed/NCBI

Kern ER, Collins DJ, Wan WB, Beadle JR, Hostetler KY and Quenelle DC: Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother. 48:3516–3522. 2004. View Article : Google Scholar : PubMed/NCBI

Chemaly RF, Hill JA, Voigt S and Peggs KS: In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review. Antiviral Res. 163:50–58. 2019. View Article : Google Scholar : PubMed/NCBI

Gagelmann N, Ljungman P, Styczynski J and Kröger N: Comparative efficacy and safety of different antiviral agents for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis. Biol Blood Marrow Transplant. 24:2101–2109. 2018. View Article : Google Scholar : PubMed/NCBI

Hostetler KY: Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art. Antiviral Res. 82:A84–A98. 2009. View Article : Google Scholar : PubMed/NCBI

Painter W, Robertson A, Trost LC, Godkin S, Lampert B and Painter G: First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother. 56:2726–2734. 2012. View Article : Google Scholar : PubMed/NCBI

Aldern KA, Ciesla SL, Winegarden KL and Hostetler KY: Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol. 63:678–681. 2003. View Article : Google Scholar : PubMed/NCBI

Ciesla SL, Trahan J, Wan WB, Beadle JR, Aldern KA, Painter GR and Hostetler KY: Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 59:163–171. 2003. View Article : Google Scholar : PubMed/NCBI

Tippin TK, Morrison ME, Brundage TM and Momméja-Marin H: Brincidofovir is not a substrate for the human organic anion transporter 1: A mechanistic explanation for the lack of nephrotoxicity observed in clinical studies. Ther Drug Monit. 38:777–786. 2016. View Article : Google Scholar : PubMed/NCBI

Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, Chittick G, Brundage TM, Wilson C, Morrison ME, et al: A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 25:369–381. 2019. View Article : Google Scholar : PubMed/NCBI

Papanicolaou GA, Silveira FP, Langston AA, Pereira MR, Avery RK, Uknis M, Wijatyk A, Wu J, Boeckh M, Marty FM and Villano S: Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: A randomized, dose-ranging, Double-blind, phase 2 study. Clin Infect Dis. 68:1255–1264. 2019. View Article : Google Scholar : PubMed/NCBI

Frange P and Leruez-Ville M: Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections. Med Mal Infect. 48:495–502. 2018. View Article : Google Scholar : PubMed/NCBI

Marty FM and Boeckh M: Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed? Curr Opin Virol. 1:555–562. 2011. View Article : Google Scholar : PubMed/NCBI

Piret J and Boivin G: Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance. Antiviral Res. 163:91–105. 2019. View Article : Google Scholar : PubMed/NCBI

Bright PD, Gompels M, Donati M and Johnston S: Successful oral treatment of Ganciclovir resistant cytomegalovirus with Maribavir in the context of primary immunodeficiency: First case report and review. J Clin Virol. 87:12–16. 2017. View Article : Google Scholar : PubMed/NCBI

Maertens J, Cordonnier C, Jaksch P, Poiré X, Uknis M, Wu J, Wijatyk A, Saliba F, Witzke O and Villano S: Maribavir for preemptive treatment of cytomegalovirus reactivation. N Engl J Med. 381:1136–1147. 2019. View Article : Google Scholar : PubMed/NCBI

Avery RK, Marty FM, Strasfeld L, Lee I, Arrieta A, Chou S, Tatarowicz W and Villano S: Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis. 12:489–496. 2010. View Article : Google Scholar : PubMed/NCBI

Germi R, Mariette C, Alain S, Lupo J, Thiebaut A, Brion JP, Epaulard O, Saint Raymond C, Malvezzi P and Morand P: Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus. Antiviral Res. 101:57–61. 2014. View Article : Google Scholar : PubMed/NCBI

Avery RK, Mossad SB, Poggio E, Lard M, Budev M, Bolwell B, Waldman WJ, Braun W, Mawhorter SD, Fatica R, et al: Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation. 90:419–426. 2010. View Article : Google Scholar : PubMed/NCBI

Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, Mohty M, Or R, Maschan M, Schumm M, et al: Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 116:4360–4367. 2010. View Article : Google Scholar : PubMed/NCBI

Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED and Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 333:1038–1044. 1995. View Article : Google Scholar : PubMed/NCBI

Blyth E, Clancy L, Simms R, Ma CK, Burgess J, Deo S, Byth K, Dubosq MC, Shaw PJ, Micklethwaite KP and Gottlieb DJ: Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood. 121:3745–3758. 2013. View Article : Google Scholar : PubMed/NCBI

Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA and Mackinnon S: Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 362:1375–1377. 2003. View Article : Google Scholar : PubMed/NCBI

Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M, Lakshmipathi S, Martin K, Bunjes D, Harsdorf S, et al: Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. Leukemia. 31:2161–2171. 2017. View Article : Google Scholar : PubMed/NCBI

Celilova S, Toret E, Adaklı Aksoy B, Ovalı E and Bozkurt C: CMV Specific T cells for treatment of CMV infection after hematopoietic stem cell transplantation in a pediatric case: First application in Turkey. Turk J Haematol. 37:65–67. 2020.PubMed/NCBI

Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, et al: Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 35:3547–3557. 2017. View Article : Google Scholar : PubMed/NCBI

Kállay K, Kassa C, Réti M, Karászi É, Sinkó J, Goda V, Stréhn A, Csordás K, Horváth O, Szederjesi A, et al: Early experience with CliniMACS prodigy CCS (IFN-gamma) system in selection of virus-specific T cells from third-party donors for pediatric patients with severe viral infections after hematopoietic stem cell transplantation. J Immunother. 41:158–163. 2018. View Article : Google Scholar : PubMed/NCBI

Ogonek J, Verma K, Schultze-Florey C, Varanasi P, Luther S, Schweier P, Kühnau W, Göhring G, Dammann E, Stadler M, et al: Characterization of high-avidity cytomegalovirus-specific T cells with differential tetramer binding coappearing after allogeneic stem cell transplantation. J Immunol. 199:792–805. 2017. View Article : Google Scholar : PubMed/NCBI

Bao L, Cowan MJ, Dunham K, Horn B, McGuirk J, Gilman A and Lucas KG: Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections. J Immunother. 35:293–298. 2012. View Article : Google Scholar : PubMed/NCBI

Koehne G, Hasan A, Doubrovina E, Prockop S, Tyler E, Wasilewski G and O'Reilly RJ: Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia. Biol Blood Marrow Transplant. 21:1663–1678. 2015. View Article : Google Scholar : PubMed/NCBI

Pei XY, Zhao XY, Chang YJ, Liu J, Xu LP, Wang Y, Zhang XH, Han W, Chen YH and Huang XJ: Cytomegalovirus-specific T-cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: The quantitative and qualitative immune recovery for cytomegalovirus. J Infect Dis. 216:945–956. 2017. View Article : Google Scholar : PubMed/NCBI

Peggs KS, Thomson K, Samuel E, Dyer G, Armoogum J, Chakraverty R, Pang K, Mackinnon S and Lowdell MW: Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis. 52:49–57. 2011. View Article : Google Scholar : PubMed/NCBI

Micklethwaite K, Hansen A, Foster A, Snape E, Antonenas V, Sartor M, Shaw P, Bradstock K and Gottlieb D: Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 13:707–714. 2007. View Article : Google Scholar : PubMed/NCBI

Houghtelin A and Bollard CM: Virus-specific T cells for the immunocompromised patient. Front Immunol. 8:12722017. View Article : Google Scholar : PubMed/NCBI

Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Löffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, et al: Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 99:3916–3922. 2002. View Article : Google Scholar : PubMed/NCBI

Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A, Capanni M, Urbani E, Mancusi A, Aversa F, et al: Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 106:4397–4406. 2005. View Article : Google Scholar : PubMed/NCBI

Gary R, Aigner M, Moi S, Schaffer S, Gottmann A, Maas S, Zimmermann R, Zingsem J, Strobel J, Mackensen A, et al: Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts. J Transl Med. 16:1242018. View Article : Google Scholar : PubMed/NCBI

Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luriá EA and Ruadkow IA: Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 2:83–92. 1974.PubMed/NCBI

Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, Scadden DT, Ma'ayan A, Enikolopov GN and Frenette PS: Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 466:829–834. 2010. View Article : Google Scholar : PubMed/NCBI

Martínez-Peinado P, Pascual-García S, Roche E and Sempere-Ortells JM: Differences of clonogenic mesenchymal stem cells on immunomodulation of lymphocyte subsets. J Immunol Res. 2018:72327172018. View Article : Google Scholar : PubMed/NCBI

Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang GB, et al: Consensus conference on clinical practice in chronic GVHD: Second-line treatment of chronic Graft-versus-Host disease. Biol Blood Marrow Transplant. 17:1–17. 2011. View Article : Google Scholar : PubMed/NCBI

Tse WT, Pendleton JD, Beyer WM, Egalka MC and Guinan EC: Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation. 75:389–397. 2003. View Article : Google Scholar : PubMed/NCBI

Malcherek G, Jin N, Huckelhoven AG, Mani J, Wang L, Gern U, Diehlmann A, Wuchter P, Schmitt A, Chen B, et al: Mesenchymal stromal cells inhibit proliferation of virus-specific CD8⁺ T cells. Leukemia. 28:2388–2394. 2014. View Article : Google Scholar : PubMed/NCBI

Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M, Christoph S, Gromke T, Kordelas L, Ottinger HD, et al: Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: Evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 118:1402–1412. 2011. View Article : Google Scholar : PubMed/NCBI

Inagaki J, Noguchi M, Kurauchi K, Tanioka S, Fukano R and Okamura J: Effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic stem cell transplantation in pediatric acute leukemia. Biol Blood Marrow Transplant. 22:300–306. 2016. View Article : Google Scholar : PubMed/NCBI

Litjens NHR, van der Wagen L, Kuball J and Kwekkeboom J: Potential beneficial effects of cytomegalovirus infection after transplantation. Front Immunol. 9:3892018. View Article : Google Scholar : PubMed/NCBI

Yoon JH, Lee S, Kim HJ, Jeon YW, Lee SE, Cho BS, Lee DG, Eom KS, Kim YJ, Min CK, et al: Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission. Oncotarget. 7:17230–17241. 2016. View Article : Google Scholar : PubMed/NCBI

Jang JE, Kim SJ, Cheong JW, Hyun SY, Kim YD, Kim YR, Kim JS and Min YH: Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. Ann Hematol. 94:275–282. 2015. View Article : Google Scholar : PubMed/NCBI